Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cybin Inc.

< Previous 1 2 3 4 5 6 7 8 9 Next >
Cybin Announces Closing of $175 Million Registered Direct Offering
From Cybin Inc.
Via Business Wire
Tickers CBOE CYBN
Cybin Announces $175 Million Registered Direct Offering
From Cybin Inc.
Via Business Wire
Tickers CBOE CYBN
Cybin Highlights Neuropsychiatry Platform and Upcoming Clinical Milestones
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the Cantor Global Healthcare Conference 2025
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Senior Leadership Changes
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Results of Annual Meeting of Shareholders
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the Canaccord Genuity 45th Annual Growth Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Receives UK MHRA Approval to Commence EMBRACE, A Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the 2025 Psychedelic Science Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin to Participate at the 28th Annual Milken Institute Global Conference
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs
From Cybin Inc.
Via Business Wire
Tickers CYBN
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
Tickers CYBN
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.